# US 2003/0078249 A1 · VLA-4 inhibitor compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0078249 A1
- Document ID: US20030078249A1
- Status: Published application
- Kind: A1
- Application number: 10/034,585
- Filed: 2001-12-28
- Published: 2003-04-24
- Earliest claimed: 1999-06-30
- Assignees: Daiichi Pharmaceutical Co., Ltd.
- Inventors: John J. Baldwin; Edward McDonald; Kevin Joseph Moriarty; Christopher Ronald Sarko; Nobuo Machinaga; Atsushi Nakayama; Jun Chiba; Shin Iimura; Yoshiyuki Yoneda
- Web page: https://patentgrep.com/patent/US20030078249A1

## CPC

- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07C 275/42: being further substituted by carboxyl groups
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 207/12: Oxygen or sulfur atoms
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 207/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 207/24: Oxygen or sulfur atoms
- C07D 209/12: Radicals substituted by oxygen atoms
- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/38: Halogen atoms or nitro radicals
- C07D 213/55: Acids; Esters
- C07D 217/02: with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D 277/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 277/48: by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
- C07D 295/13: to an acyclic saturated chain
- C07D 295/185: from aliphatic carboxylic acids
- C07D 307/33: in position 2, the oxygen atom being in its keto or unsubstituted enol form
- C07D 311/20: hydrogenated in the hetero ring
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/02: containing two hetero rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 491/04: Ortho-condensed systems
- C07C 2601/02: with a three-membered ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Compounds that selectively inhibit the binding of ligands to α4β1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: 1 As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.

## Claims

### Claim 1

A compound represented by Formula I, or a salt thereof,
1884
wherein
W is chosen from aryl group, substituted aryl group, heteroaryl group and substituted heteroaryl group;
W1 is chosen from arylene group, substituted arylene group, heteroarylene group and substituted heteroarylene group;
A is chosen from ═O, ═S and ═NH;
R is chosen from a direct bond, alkyenylene group and —(CH2)n—, wherein
n is chosen from 1 and 2;
X is chosen from —C(O)—, —CH2— and S(O)2;
M is chosen from
1885
wherein
1886
is a divalent 4-, 5-, 6- or 7-membered heterocyclic moiety,
wherein the nitrogen atom is the point of attachment to X;
R1, R2 and R3 are independently chosen from —H, —O, —NH2, halogen atom, alkyl group, substituted alkyl group, aryl group, substituted aryl group, alkoxy group, substituted alkoxy group, monoalkylamino group, substituted monoalkylamino group, dialkylamino group, substituted dialkylamino group, cycloalkylamino group, substituted cycloalkylamino group, alkylsulfonylamino group, substituted alkylsulfonylamino group, arylsulfonylamino group, substituted arylsulfonylamino group, aryloxy group, substituted aryloxy group, heteroaryloxy group, substituted heteroaryloxy group, benzyloxy group and substituted benzyloxy group, or
two of R1, R2 and R3 taken together may form a 3-, 4-, 5-, 6-, or 7-membered carbocyclic or heterocyclic residues optionally substituted with from 1 to 3 substituents chosen independently from —OH, halogen atom, —NH2, alkyl group, alkoxy group, aryl group, aryloxy group, alkylamino group, benzyloxy group and heteroaryl group;
R4 is chosen from —H and lower alkyl group;
Y is a direct bond or a divalent radical chosen from —C(O)—, —C(O)NH—, alkenylene group, alkynylene group and —(CH2)kY2, wherein
k is chosen from 1, 2 and 3; and
Y2 is a direct bond or a divalent radical chosen from —O—, —S—, —S(O), —S(O)2— and —NY3—, wherein
Y3 is chosen from —H and lower alkyl group;
Z is chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group;
A1 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group, —(CH2)t— and —O(CH2)v, wherein
t is chosen from 1, 2 and 3; and
v is chosen from 0, 1, 2, and 3; and
R5 is chosen from —OH, lower alkoxy group, —N(H)OH,
1887
wherein
1888
is a divalent 4-, 5-, 6- or 7-membered heterocyclic moiety, wherein
the nitrogen atom is the point of attachment to X;
R6 and R7 are independently chosen from —H, —OH, halogen atom, alkyl group and alkoxy group;
Y1 is a divalent radical chosen from —O—, —S—, —S(O)—, —S(O)2— and —NY4—, wherein
Y4 is chosen from —H and lower alkyl group;
Z1 is a divalent radical chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group;
A2 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group and —(CH2)e wherein
e is chosen from 1, 2 and 3; and
R8 is chosen from —OH, lower alkoxy group, —N(H)OH,
1889
wherein
L is
1890
wherein
1891
is a divalent 4-, 5-, 6- or 7-membered heterocyclic moiety, optionally substituted with from 1 to 3 substitutents chosen independently from alkyl group, alkoxy group, hydroxyalkyl group, —OH, benzyloxy group, —NH2, halogen atom, aryl group and heteroaryl group, said moiety may be fused to 1 or 2 additional carbocyclic or heterocyclic residues optionally substituted with from 1 to 3 substitutents chosen independently from alkyl group, aryloxy group, alkoxy group, hydroxyallyl group, —OH, benzyloxy group, —NH2,, halogen atom, aryl group and heteroaryl group;
m and q are independently chosen from 0, 1, 2 and 3;
X1 is chosen from —CH—and —N═;
R9 is chosen from —H and lower alkyl group;
R10 is chosen from —COOH, lower alkoxycarbonyl group,
1892
Z2 is chosen from —H, COOH and lower alkoxycarbonyl group; and
1893
wherein
R11 is chosen from —O—,
1894
and —NR12— wherein
R12 is chosen from —H, alkyl group, substituted alkyl group, cycloalkyl group, substituted cycloalkyl group, aryl group, substituted aryl group, benzyl group, substituted benzyl group, lower alkenyl group, substituted lower alkenyl group and lower alkynyl group
the left hand bond is the point of attachment to —X— and the right hand bond is the point of attachment to —Z3;
Z3 is chosen from a direct bond, a divalent aliphatic hydrocarbon moiety having 1 to 12 carbon atoms, wherein
one or more carbon atoms may be replaced with —O— or —NR13— wherein
R13 is chosen from —H and lower alkyl group, and one or more hydrogen atoms attached to an aliphatic carbon atom may be replaced with lower alkyl group; and
1895
wherein
x is chosen from 0 and 1;
y is chosen from 1, 2, and 3; and
R14 is chosen from —H, —OH and halogen atom,
1896
and, when R11 is —NR12,
1897
wherein
Z4 is chosen from
1898
wherein
R14a is chosen from —H, —OH, lower alkyl group
and halogen atom;
1899
wherein the left hand bond is the point of attachment to R11 and the right hand bond is the point of attachment to Q2;
Q2 is a divalent radical chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group, substituted cycloalkylene group,
1900
wherein R15 and R16 are independently chosen from —H, halogen atom and lower alkyl group; and
1901
wherein R17 and R18 are independently chosen from —H, lower alkyl group, substituted lower alkyl group and lower alkenyl group; and
L1 is chosen from —COOH and —COOR19 wherein
R19 is a lower alkyl group.

### Claim 2 (depends on 1)

A compound according to claim 1, or a salt thereof, wherein M is
1902

### Claim 3 (depends on 1)

A compound according to claim 1, or a salt thereof, wherein M is
1903

### Claim 4 (depends on 1)

A compound according to claim 1, or a salt thereof, wherein M is
1904

### Claim 5 (depends on 1)

A compound according to claim 1, or a salt thererof, wherein M is
1905

### Claim 6 (depends on 2)

A compound according to claim 2, or a salt thereof, wherein at least one radical of R1, R2 and R3 is —OH or halogen atom.

### Claim 7 (depends on 6)

A compound according to claim 6, or a salt thereof, wherein A is ═O, R is —(CH2)n— and X is —C(O)—.

### Claim 8 (depends on 7)

A compound according to claim 7, or a salt thereof, wherein Y is chosen from alkenylene group, alkynylene group and —(CH2)kY2; Y2 is chosen from a direct bond, —O—, —S(O) and —NY3—; and Y3 is —H.

### Claim 9 (depends on 8)

A compound according to claim 8, or a salt thereof, wherein Y is chosen from —O— and —NY3—.

### Claim 10 (depends on 2)

A compound according to claim 2, or a salt thereof, wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof.

### Claim 11 (depends on 10)

A compound according to claim 10, or a salt thereof, wherein W1 is unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to the —NH— thereof.

### Claim 12 (depends on 2)

A compound according to claim 2, or a salt thereof, wherein W1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to the —NH— thereof and having 1 to 3 substituents chosen from lower allyl group and halogen atom.

### Claim 13 (depends on 2)

A compound according to claim 2, or a salt thereof, wherein A1 is a direct bond or —(CH2)t—.

### Claim 14 (depends on 13)

A compound according to claim 13, or a salt thereof, wherein A1 is a direct bond.

### Claim 15 (depends on 14)

A compound according to claim 14, or a salt thereof, wherein R5 is —OH.

### Claim 16 (depends on 2)

A compound according to claim 2, or a salt thereof, wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof; W1 is unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to the —NH— thereof; R is —CH2—; X is —C(O)— and R5 is —OH.

### Claim 17 (depends on 16)

A compound according to claim 16, or a salt thereof, chosen from the group consisting of
1906

### Claim 18 (depends on 17)

A compound according to claim 17, or a salt thereof, chosen from the grow consisting of
1907

### Claim 19 (depends on 2)

A compound according to claim 2, or a salt thereof, wherein R5 is lower alkoxy group.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method of inhibiting cell adhesion in a mammal, said method comprising administering to said mammal an effective amount of a compound according to any of claims 1 to 19.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method of treating a condition associated with VLA-4 mediated cell adhesion in a mammal, aid method comprising administering to said mammal an effective amount of a compound according to any of claims 1 to 19.

### Claim 22 (depends on 21)

A method according to claim 21, wherein the condition associated with VLA-4 mediated cell adhesion is chosen from inflammatory responses, autoimmune responses and tumor metastasis.

### Claim 23 (depends on 21)

A method according to claim 21, wherein the condition associated with VLA-4 mediated cell adhesion is chosen from asthma, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and transplantation rejection.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Use of a compound according to any of claims 1-19 for therapy.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Use of a compound according to any of claims 1-19 in the manufacture of a medicament for the treatment of a condition associated with VLA-4 mediated cell adhesion.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A pharmaceutical composition comprising as a therapeutic agent, a compound according to any of claims 1 to 19 and a pharmaceutically acceptable carrier or excipient.

### Claim 27 (depends on 26)

A pharmaceutical composition according to claim 26, further comprising one or more additional therapeutic agents.

### Claim 28 (depends on 27)

A pharmaceutical composition according to claim 27, wherein said one or more additional therapeutic agents are chosen from the group consisting of antiinflammatory, antirheumatic, corticosteroid, immunosuppressive, antipsoriatic, bronchodilator, antiasthmatic and antidiabetic agents.

### Claim 29 (depends on 28)

A pharmaceutical composition according to claim 28, wherein one of said one or more additional therapeutic agents is an antiinflamatory agent.

### Claim 30 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said antiinflammatory agent is chosen from a steroid and an NSAID.
